Related references
Note: Only part of the references are listed.Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma
Gerard Reid et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2019)
Bilateral Anterior Uveitis Associated with Nivolumab Therapy
Justin Karlin et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2018)
HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy
Taku Fujimura et al.
JOURNAL OF DERMATOLOGY (2018)
CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects
Lauren A. Dalvin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient
Takashi Arai et al.
JOURNAL OF DERMATOLOGY (2017)
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient
Hiroaki Kanno et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity
Pui Ying Chan et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
Bilateral uveitis and macular edema induced by Nivolumab: a case report
Claire Theillac et al.
BMC OPHTHALMOLOGY (2017)
Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report
Daniel Russell Richardson et al.
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma
Toshihiko Matsuo et al.
CLINICAL CASE REPORTS (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma
Marion Bricout et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report
Alfred Basilious et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2016)
PD-1/PD-L and autoimmunity: A growing relationship
Mohammad Reza Zamani et al.
CELLULAR IMMUNOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab
Khawla Abu Samra et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Stefan Diem et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes
Marcelo Mendes Lavezzo et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma
Kirollos S. Hanna
PHARMACOTHERAPY (2016)
Clinical Images: Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment
Guillermo de Velasco et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
J. Gao et al.
ONCOGENE (2015)
CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: A Systematic Review and Meta-analysis
Tingkun Shi et al.
SCIENTIFIC REPORTS (2014)
The Standardization of Uveitis Nomenclature (SUN) Project Development of a Clinical Evidence Base Utilizing Informatics Tools and Techniques
B. Trusko et al.
METHODS OF INFORMATION IN MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma
Steven Yeh et al.
OPHTHALMOLOGY (2009)
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
Douglas C. Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunotherapy of autoimmunity and cancer: the penalty for success
Rachel R. Caspi
NATURE REVIEWS IMMUNOLOGY (2008)
Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma:: an 11-year follow-up
S Aisenbrey et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2003)
Share Paper
